Clinical Takeaway — Series Overview
What You Need to Know Before Reading Further
FDA-Approved on This List
1 of 17
(PT-141 / Bremelanotide)
Phase 3 Completed — Failed
1 of 17
(AOD-9604 — no efficacy)
Zero Published Human Trials
5 of 17
(MOTS-C, KPV, Epitalon, LL-37, MT-II)
Phase 1–2 Data Only
4 of 17
(CJC-1295, Ipamorelin, GHRP-2/6)
Category 2 means a compounding pharmacy cannot legally make it— it does not mean the compound is dangerous, and it does not mean it is safe.
RFK Jr.'s proposed reclassification to Category 1 allows legal compounding with a prescription. It does not constitute FDA approval, and does not change the evidence base one iota.
The wellness claims being marketed for most of these peptides — tissue repair, cognitive enhancement, longevity, fat loss —have not been tested in controlled human trials for any of these compounds.
The FDA's three-phase approval standard exists because animal studies routinely look better than human outcomes. Most of these compounds have never left the animal data phase.